TY  - JOUR 
AU  - Raje, Noopur
AU  - Terpos, Evangelos
AU  - Willenbacher, Wolfgang
AU  - Shimizu, Kazuyuki
AU  - García Sanz, Ramón
AU  - Durie, Brian
AU  - Legieć, Wojciech
AU  - Krejčí, Marta
AU  - Laribi, Kamel
AU  - Zhu, Li
AU  - Cheng, Paul
AU  - Warner, Douglas
AU  - Roodman, G. David
PY  - 2018
SN  - 1470-2045
UR  - http://hdl.handle.net/10366/155433
AB  - [EN]Multiple myeloma is characterised by monoclonal paraprotein production and osteolytic lesions, commonly leading to skeletal-related events (spinal cord compression, pathological fracture, or surgery or radiotherapy to affected bone). Denosumab, a...
LA  - eng
PB  - Elsevier
KW  - Myeloma
KW  - Zoledronic Acid
KW  - Denosumab
KW  - Bone Disease
KW  - Randomized trial
KW  - Aged
KW  - Bone Density Conservation Agents
KW  - Multiple Myeloma
KW  - Spinal Cord Compression
KW  - Time Factors
KW  - Bone Neoplasms
KW  - Risk Factors
KW  - Treatment Outcome
KW  - Humans
KW  - Antineoplastic Agents
KW  - Middle Aged
KW  - Double-Blind Method
TI  - Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study
DO  - 10.1016/S1470-2045(18)30072-X
T2  - Lancet Oncology
VL  - 19
M2  - 370
ER  -